$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

2023-08-30

2026-02-28

2026-02-28

50

Study Overview

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol. The investigators hypothesize the anticancer activity of low dose OXIRI (LD-OXIRI) regimen comprising of metronomic oxaliplatin (O) and metronomic capecitabine (xeloda; X) in combination with UGT1A1-directed dosing of irinotecan (IRI) to be a tolerable regimen in patients with advanced PDAC and will lead to a favourable response rate. Patients will be prospectively enrolled in two stages - In stage 1, patients will be recruited and evaluated for response and toxicity. In stage 2, more patients will be recruited for further evaluation of response and toxicity.

Eligible patients will be recruited from the National Cancer Centre, Singapore (NCCS). Patients will be referred for assessment by the primary physician to a study investigator for screening. Informed written consent for entry into the trial will be obtained from the patient by a delegated investigator. All patients eligible for study entry will receive the LD-OXIRI regimen at the National Cancer Centre, Singapore. All concomitant medication taken during the study must be recorded. If a drug is administered prophylactically, this must be noted. The patients will not receive any other investigational drugs while on this study. There will be a screening period of 28 days, a treatment period till disease progression or unacceptable toxicity, and a post-treatment follow up period of up to 24 months.

  • Metastatic Pancreatic Cancer
  • DRUG: Low Dose OXIRI (LD-OXIRI)
  • LDOXIRI-PDAC-01

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2023-04-24  

N/A  

2025-06-10  

2023-06-29  

N/A  

2025-06-11  

2023-07-03  

N/A  

2025-06  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Low Dose OXIRI (LD-OXIRI)

Low Dose OXIRI (LD-OXIRI) regimen comprises Metronomic Oxaliplatin (O) and Metronomic Capecitabine (xeloda; X) in combination with UGT1A1-directed dosing of Irinotecan (IRI).

DRUG: Low Dose OXIRI (LD-OXIRI)

  • The LD-OXIRI regimen will be administered in the following sequence: * metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis; * intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 mi
Primary Outcome MeasuresMeasure DescriptionTime Frame
Overall Response Rate (ORR).The proportion of patients who have a partial or complete response as specified in RECIST 1.1.Up to 3 years.
Clinical Benefit Rate (CBR).The percentage of advanced cancer patients who achieve complete response, partial response, or at least six months of stable disease as specified in RECIST 1.1.Up to 3 years.
The Grade 3-5 Toxicity Rate.The proportion of patients who have adverse event(s) with Grade 3-5 toxicity as defined in CTCAE 5.0.Up to 3 years.
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Maximum plasma concentration [(Cmax)] of low dose Capecitabine and its intermediary metabolites (5'-deoxy-5-fluorocytidine [DFCR] and 5'- deoxy-5-fluorouridine [DFUR]) and 5FU.Maximum plasma concentration [(Cmax)] of low dose capecitabine and its intermediary metabolites (5'-deoxy-5-fluorocytidine [DFCR] and 5'- deoxy-5-fluorouridine [DFUR]) and 5FU at Cycle 1 Day 1.At predose, 1 hr, end of irinotecan infusion on Cycle 1 Day 1 (each cycle is 21 days)
Trough concentration of low dose capecitabine and its intermediary metabolites and 5FU.Trough concentration of low dose capecitabine and its intermediary metabolites (5'-deoxy-5-fluorocytidine [DFCR] and 5'- deoxy-5-fluorouridine [DFUR]) and 5FU.At predose of Cycle 2 Day 1 and Cycle 3 Day 1 (each cycle is 21 days)
Immunophenotyping from extracted peripheral blood mononuclear cells (PBMCs) - measurement of cytokine and chemokine concentrations in picograms per milliliters using multiplex flow cytometry.Immunophenotyping from extracted peripheral blood mononuclear cells (PBMCs) - measurement of cytokine and chemokine concentrations in picograms per milliliters using multiplex flow cytometry at these time-points: at predose, end of oxaliplatin infusion, end of irinotecan infusion on Cycle 1 Day 1 (each cycle is 21 days); at predose of Cycle 2 Day 1 and at disease progression (up to three years).Up to 3 years.
Genomic analysis of circulating tumour DNA (ctDNA).Genomic analysis of circulating tumour DNA (ctDNA) from whole blood at these time-points: at predose of every two cycles (Cycle 1 Day 1, Cycle 3 Day 1, Cycle 5 Day 1, etc - each cycle is 21 days) and at disease progression (up to three years).Up to 3 years.
Identification of exosomal proteins secreted by extracellular vesicles from plasma.Identification of exosomal proteins secreted by extracellular vesicles from plasma using mass spectrometry, at the following time-points: at predose, end of oxaliplatin infusion, end of irinotecan infusion on Cycle 1 Day 1 (each cycle is 21 days); at predose of Cycle 2 Day 1 and at disease progression (up to three years).Up to 3 years.
Progression-free survival (PFS).Time from first dose of treatment to disease progression or death, whichever comes first.Up to 3 years.
Overall survival (OS).Time from first dose to death.Up to 3 years.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Dr Joycelyn LEE, MBBS, MRCP (UK), M Med

Phone Number: +65 64368000

Email: joycelyn.lee.j.x@singhealth.com.sg

Study Contact Backup

Name: Tze Wei LIM

Phone Number: +65 64368000

Email: lim.tze.wei@singhealth.com.sg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
21 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    The patient must meet all of the inclusion criteria to participate in the study.
    1. Aged above 21 2. Histopathological diagnosis of pancreatic cancer 3. Advanced disease not amenable to curative resection (locally advanced or metastatic disease) 4. Measureable disease by RECIST 1.1 criteria 5. Life expectancy of at least 12 weeks 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 7. Adequate hematologic function (granulocyte count ≥ 1.5 × 10**9/L, platelet count ≥ 100 × 10**9/L), 8. Adequate hepatic function (total bilirubin ≤ 1.5 x the upper limits of normal [ULN], AST and ALT, ALP ≤ 3 x ULN or < 5 x ULN in case of hepatic involvement), 9. Adequate renal function (creatinine clearance > 50 mL/min) will be eligible for inclusion into the study. 10. Able to provide written and informed consent
    Exclusion Criteria:
    Any patient meeting any of the exclusion criteria at baseline will be excluded from participation.
    1. History of another malignancy within 5 years prior to registration. Patients with a past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and superficial transitional cell carcinoma of the bladder are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease free after definitive primary treatment for at least 5 years. 2. Untreated CNS metastases or leptomeningeal disease. Patients with brain metastases that have been treated, and are asymptomatic, and have been stable for 3 or more months after treatment are allowed. A baseline CT or MRI brain is only required if there is clinical suspicion of CNS involvement. 3. Concurrent illness, including severe infection, that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety 4. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol 5. Treatment with palliative chemotherapy or radiotherapy within 4 weeks prior to enrolment into the study 6. Major surgery within two weeks prior to enrolment into the study 7. Patients on chronic immunosuppressive therapy 8. Pregnancy, lactation or inadequate contraception. Women of childbearing potential must have a negative pregnancy test within 3 days of enrolment and agree to use a reliable means of contraception. Men must have been surgically sterilised or agree to use a barrier method of contraception 9. Patients on anticoagulant therapy with vitamin K antagonists.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • National Medical Research Council (NMRC), Singapore
  • PRINCIPAL_INVESTIGATOR: Dr Joycelyn LEE, MBBS, MRCP (UK), M Med, National Cancer Centre, Singapore

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate